Osmosis Investment Management UK Ltd Purchases Shares of 4,630 IQVIA Holdings Inc. $IQV

Osmosis Investment Management UK Ltd acquired a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV) in the second quarter, according to the company in its most recent filing with the SEC. The firm acquired 4,630 shares of the medical research company’s stock, valued at approximately $895,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Financial Freedom LLC purchased a new position in IQVIA during the first quarter valued at approximately $25,000. Ascentis Independent Advisors purchased a new stake in IQVIA in the 1st quarter worth approximately $25,000. International Assets Investment Management LLC purchased a new stake in IQVIA in the 4th quarter worth approximately $27,000. Compass Financial Management LLC acquired a new stake in shares of IQVIA during the 2nd quarter worth approximately $27,000. Finally, Gilpin Wealth Management LLC purchased a new position in shares of IQVIA during the 4th quarter valued at approximately $27,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Price Performance

Shares of NYSE IQV opened at $260.30 on Tuesday. The firm has a 50-day simple moving average of $214.97 and a 200-day simple moving average of $187.62. The company has a quick ratio of 0.71, a current ratio of 0.71 and a debt-to-equity ratio of 2.18. The stock has a market capitalization of $42.85 billion, a price-to-earnings ratio of 32.30, a price-to-earnings-growth ratio of 2.21 and a beta of 1.18. IQVIA Holdings Inc. has a 52 week low of $154.50 and a 52 week high of $261.88.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, topping analysts’ consensus estimates of $3.03 by $0.12. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The firm had revenue of $4.37 billion for the quarter, compared to analyst estimates of $4.30 billion. During the same period in the previous year, the business posted $2.81 earnings per share. IQVIA’s quarterly revenue was up 8.7% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, equities analysts predict that IQVIA Holdings Inc. will post 11.57 earnings per share for the current fiscal year.

IQVIA declared that its Board of Directors has authorized a stock repurchase plan on Thursday, May 7th that permits the company to buyback $2.00 billion in outstanding shares. This buyback authorization permits the medical research company to buy up to 6.8% of its shares through open market purchases. Shares buyback plans are generally an indication that the company’s management believes its stock is undervalued.

Insider Buying and Selling

In other news, insider Keriann Cherofsky sold 558 shares of the company’s stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total value of $136,827.18. Following the completion of the sale, the insider directly owned 2,989 shares in the company, valued at $732,932.69. This represents a 15.73% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Bhavik Patel sold 1,855 shares of the stock in a transaction that occurred on Friday, July 31st. The shares were sold at an average price of $235.27, for a total value of $436,425.85. Following the completion of the sale, the insider directly owned 1,348 shares of the company’s stock, valued at approximately $317,143.96. This represents a 57.91% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 12,913 shares of company stock valued at $3,098,793. 1.70% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of analysts recently issued reports on the stock. Morgan Stanley reissued an “equal weight” rating and set a $200.00 price target (down from $225.00) on shares of IQVIA in a report on Wednesday, June 17th. Barclays reaffirmed an “overweight” rating on shares of IQVIA in a report on Tuesday, July 28th. Royal Bank Of Canada increased their target price on shares of IQVIA from $221.00 to $247.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 29th. Deutsche Bank Aktiengesellschaft set a $240.00 target price on IQVIA in a research report on Thursday, July 9th. Finally, TD Cowen upped their price target on IQVIA from $233.00 to $288.00 and gave the stock a “buy” rating in a report on Wednesday, July 29th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, IQVIA has an average rating of “Moderate Buy” and a consensus price target of $241.88.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.